The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib.

Autor:	Salame H; Internal Medicine, Lebanese University Faculty of Medicine, Beirut, LBN., Mckey R; Internal Medicine, Lebanese University Faculty of Medicine, Beirut, LBN., Ballout M; Cardiology, Hospital Center Agglomeration De Nevers, Nevers, FRA., Saad W; Oncology, Al Zahraa Hospital University Medical Center, Beirut, LBN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Dec 21; Vol. 13 (12), pp. e20588. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021).
DOI:	10.7759/cureus.20588
Abstrakt:	We present the first reported case of stage 4 thymoma with pleural metastases that was found to be driven by the neurotrophic tyrosine receptor kinase (NTRK)-fusion gene. The patient was started on chemotherapy but it was discontinued due to intolerable side effects. Alternative options in such patients with rare diseases are limited; in fact, many concerns exist regarding the safety and efficacy of newly approved agents for the treatment of advanced thymomas, such as pembrolizumab and sunitinib. Due to NTRK-fusion gene positivity, entrectinib, a novel NTRK-fusion inhibitor, was then initiated. This drug has shown an objective response of 57% in treating NTRK fusion-positive solid tumors of 19 different histological subtypes, predominantly sarcomas, non-small cell lung cancer (NSCLC), and mammary analogue secretory carcinoma of the salivary gland. However, it has never been assessed in the treatment of thymomas. After 10 months of follow-up, the patient showed a significant response with mild adverse events, which was managed by temporary discontinuation of the drug. This case highlights the crucial role of whole-genome sequencing and tissue-agnostic antineoplastics in the future of cancer treatment. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Salame et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu